-
-
-
-
-
-
-
Replimune receives FDA rejection letter for melanoma treatment
-
-
-
-
-
-
-
ProMIS Neurosciences receives FDA fast track status for Alzheimer's drug
-
-
-
-
-
-
-
Cognition Therapeutics publishes zervimesine study data
-
-
-
-
-
-
-
Oruka gets FDA clearance for psoriasis drug trial
-
-
-
-
-
-
-
FDA Investigating Whether Sarepta's (SRPT) Elevidys Should Stay On The Market - Bloomberg
-
-
-
-
-
-
-
Viatris phase 3 blepharitis drug study fails to meet primary endpoint
-
-
-
-
-
-
-
ENHERTU plus pertuzumab gets FDA breakthrough therapy designation
-
71,257 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.